Table 1.
Baseline patient and tumor characteristics of 694 patients treated with neoadjuvant chemotherapy by tumor subtype.
| Characteristic | All Patients (n = 694) | Triple- Negative (n = 170) | HER2-Positive (n = 207) | Hormone- Receptor- Positive, HER2- Negative (n = 317) | P Value |
|---|---|---|---|---|---|
| Patient age, years | 0.24 | ||||
| <50 | |||||
| 50+ | 349 (50.3) | 77 (45.3) | 103 (49.8) | 169 (53.3) | |
| 345 (49.7) | 93 (54.7) | 104 (50.2) | 148 (46.7) | ||
| T category at presentation | 0.46 | ||||
| T0 | 9 (1.3) | 3 (1.8) | 4 (1.9) | 2 (0.6) | |
| Tis | 1 (0.1) | 0 | 1 (0.5) | 0 | |
| T1 | 90 (13.0) | 24 (14.1) | 23 (11.1) | 43 (13.6) | |
| T2 | 383 (55.3) | 100 (58.8) | 108 (52.2) | 175 (55.4) | |
| T3 | 178 (25.7) | 37 (21.8) | 61 (29.5) | 80 (25.3) | |
| T4 | 32 (4.6) | 6 (3.5) | 10 (4.8) | 16 (5.1) | |
| Clinical tumor size at baseline, median (range), cm | 4.0 (0.8-15.1) | 4.0 (0.8-15.0) | 4.5 (0.8-15.1) | 4.0 (0.9-15.0) | 0.077 |
| Clinical tumor size at baseline, cm | 3 (0.4) | 1 (0.3) | 0.44 | ||
| 37 (5.5) | 1 (0.6) | 1 (0.5) | 17 (5.4) | ||
| <1.0 | 111 (16.3) | 11(6.7) | 9 (4.4) | 50 (16.0) | |
| 1.0-1.9 | 126 (18.5) | 33 (20.1) | 28 (13.7) | 63 (20.1) | |
| 2.0-2.9 | 132 (19.4) | 24 (14.6) | 39 (19.1) | 60 (19.2) | |
| 3.0-3.9 | 272 (39.9) | 38 (23.2) | 34 (16.7) | 122 (39.0) | |
| 4.0-4.9 | 13 | 57 (34.8) | 93 (45.6) | 4 | |
| ≥ 5.0 | 6 | 3 | |||
| Unknown | |||||
| Nodal category at presentation | |||||
| N1 | 658 (94.8) | 159 (93.5) | 196 (94.7) | 303 (95.6) | |
| N2 | 36 (5.2) | 11 (6.5) | 11 (5.3) | 14 (4.4) | |
| Chemotherapy received | <0.0001 | ||||
| Anthracycline + taxane | 520 (74.9) | 135 (79.4) | 117 (56.5) | 268 (84.5) | |
| Anthracycline, no taxane | 43 (6.2) | 11 (6.5) | 11 (5.3) | 21 (6.6) | |
| Taxane, no anthracycline | 119 (17.2) | 18 (10.6) | 76 (36.7) | 25 (7.9) | |
| Other | 12 (1.7) | 6 (3.5) | 3 (1.4) | 2 (1.0) |